, Volume 70, Issue 12, pp 1672–1676 | Cite as

Paraoxonase 1 activity and polymorphisms in multiple sclerosis patients

  • Monika ĎurfinováEmail author
  • Radka Bartová
  • L’ubica Procházková
  • Darina Petrleni čová
  • Pavel Sýkora
  • Vanda Repiská
Section Cellular and Molecular Biology


The pathophysiology of multiple sclerosis (MS) includes also the vascular abnormalities. Recent reports on changes in venous cerebrospinal outflow and the investigation of immunomodulatory properties of several vascular mediators on the molecular level have added new information to hypotheses on vascular pathology as determining factor in the pathophysiology of MS. We assessed changes in serum paraoxonase 1 (PON1) activities in MS patients and polymorphism of PON1 as a risk factor for MS. The main role of serum PON1 is hydrolysis of lipid peroxides and protection of low-density lipoprotein particles from oxidation. These events could play a role in lowering the risk of atherogenesis and vascular complications development in MS. There are controversial results about association of two main polymorphisms in paraoxonase coding region (PON1 55L/M, PON1 192Q/R) and risk of MS in different populations. Our results support studies that PON1 polymorphisms are probably not a risk factor of MS development.

Key words

paraoxonase genetic polymorphism multiple sclerosis 



Expanded Disability Status Scale


high-density lipoprotein


low-density lipoprotein


multiple sclerosis




relapsing-remitting multiple sclerosis


secondary progressive multiple sclerosis


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allen N.B., Lichtman J.H., Cohen H.W., Fang J., Brass L.M. & Alderman M.H. 2008. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology 30: 234–238.CrossRefGoogle Scholar
  2. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R. & Bisgaier C.L. 1999. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol. Med. 26: 892–904.CrossRefGoogle Scholar
  3. Bassett C.N. & Montine T.J. 2003. Lipoproteins and lipid peroxidation in Alzheimer’s disease. J. Nutr. Health Aging 7: 24–29.PubMedGoogle Scholar
  4. Diekstra F.P., Beleza-Meireles A., Leigh N.P., Shaw C.E. & Al-Chalabi A. 2009. Interaction between PON1 and population density in amyotrophic lateral sclerosis. Neuroreport 20: 186–190.CrossRefGoogle Scholar
  5. Draganov D.I. & La Du B.N. 2004. Pharmacogenetics of paraox-onases: a brief review. Naunyn Schmiedebergs Arch. Pharmacol. 369: 78–88.Google Scholar
  6. Duric G., Svetel M., Nikolaevic S.I., Dragadevic N., Gavrilovic J. & Kostic V.S. 2007. Polymorphism in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson’s disease. Vojnosanitetski Pregled 64: 25–30.CrossRefGoogle Scholar
  7. Ferretti G., Bacchetti T., Principi F., Di Ludovico F., Viti B., Angeleri V.A., Danni M. & Provinciali L. 2005. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult. Scler. 11: 677–682.CrossRefGoogle Scholar
  8. Hadjigeorgiou G.M., Malizos K., Dardiotis E., Aggelakis K., Dardioti M., Zibis A., Dimitroulias A., Scarmeas N., Tsezou A. & Karantanas A. 2007. Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions. J. Orthop. Res. 25: 1087–1093.CrossRefGoogle Scholar
  9. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J. & Furlong C.E. 1993. The molecular-basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73–76.CrossRefGoogle Scholar
  10. Christiansen C.F., Christiansen S., Farkas D.K., Miret M., Sorensen H.T. & Pedersen L. 2010. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 35: 267–274.CrossRefGoogle Scholar
  11. Imai Y., Morita H., Kurihara H., Sugiyama T., Kato N., Ebihara A., Hamada C., Kurihara Y., Shindo T., Oh-Hashi Y. & Yazaki Y. 2000. Evidence for association between paraoxonase gene polymorphism and atherosclerotic diseases. Atherosclerosis 149: 435–442.CrossRefGoogle Scholar
  12. Inglese M., Park S.J., Johnson C., Babb J.S., Miles L., Jaggi H., Herbert J. & Grossman R.I. 2007. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch. Neurol. 64: 196–202.Google Scholar
  13. Jamroz-Wisniewska A., Beltowski J., Stelmasiak Z. & Bartosik-Psujek H. 2009. Paraoxonase 1 activity in different types of multiple sclerosis. Mult. Scler. 15: 399–402.CrossRefGoogle Scholar
  14. Law M., Saindane A.M., Ge Y., Babb J.S., Johnson G., Mannon L.J., Herbert J. & Grossman R.I. 2004. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 231: 645–652.CrossRefGoogle Scholar
  15. Levine S.M. 1992. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med. Hypotheses 39: 271–274.CrossRefGoogle Scholar
  16. Martínez C., García-Martín E., Benito-León J., Calleja P., Díaz-Sanchez M., Pisa D., Alonso-Navarro H., Ayuso-Peralta L., Torrecilla D., Agńdez J.A.G. & Jiménez-Jiménez F.J. 2010. Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis. Neuromol. Med. 12: 217–223.CrossRefGoogle Scholar
  17. Moghtaderi A., Hashemi M., Sharafaddinzadeh N., Dabiri S., Moazeni-Roodi A., Ramroodi N. & Zolfaghari M. 2011. Lack of association between paraoxonase 1 Q192R polymorphism and multiple sclerosis in relapse phase: a case-control study. Clin. Biochem. 44: 795–798.CrossRefGoogle Scholar
  18. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O’Connor P., S andberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B. & Wolinsky J.S. 2011. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69: 292–302.CrossRefGoogle Scholar
  19. Shin B.S., Oh S.Y., Kim Y.S. & Kim K.W. 2008. The paraoxonase gene polymorphism in stroke patients and lipid profile. Acta Neurol. Scand. 117: 237–243.CrossRefGoogle Scholar
  20. Sidoti A., Antognelli C., Rinaldi C., D’Angelo R., Dattola V., Girlanda P., Talesa V. & Amato A. 2007. Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Mult. Scler. 13: 446–453.CrossRefGoogle Scholar
  21. Sýkora P., Repiská V. & Halčák L. 2010. Establishment of paraoxonase and arylesterase activity of paraoxonase 1 (PON1) in dependence on 55(L/M) and 192(Q/R) DNA polymorphism in adult people with Down syndrome. Journal of Special Education and Rehabilitation 11: 103–113.Google Scholar
  22. Zamboni P., Galeotti R., Menegatti E., Malagoni A.M., Tacconi G., Dall’Ara S., Bartolomei I. & Salvi F. 2009. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 80: 392–399.CrossRefGoogle Scholar

Copyright information

© Slovak Academy of Sciences 2015

Authors and Affiliations

  • Monika Ďurfinová
    • 1
    Email author
  • Radka Bartová
    • 1
  • L’ubica Procházková
    • 2
  • Darina Petrleni čová
    • 2
  • Pavel Sýkora
    • 3
  • Vanda Repiská
    • 4
  1. 1.Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of MedicineComenius UniversityBratislavaSlovakia
  2. 2.2nd Department of Neurology, Faculty of MedicineComenius UniversityBratislavaSlovakia
  3. 3.Department of SurgeryMalackySlovakia
  4. 4.Institute of Medical Biology, Genetic and Clinical Genetics, Faculty of MedicineComenius UniversityBratislavaSlovakia

Personalised recommendations